CKD progression composite outcome was decreased within the GLP1-RA group as compared to DPP4i group, with 2.23% of patients within GLP1-RA group having significant progression of CKD as compared to 3.46% within the DPP4i group (OR 0.64., 95% CI 0.56–0.73, p < 0.001). This evidence concerns the gene GCG and chronic kidney disease.